The purpose of the trial is to test a potential new treatment for depressive symptoms and depression-induced cognitive problems, including issues with memory, concentration, decision-making and the like.
This trial investigates the effectiveness of an oral medication called Xanamem® in improving cognitive and depressive symptoms.
Xanamem® was created to block the excess production of cortisol – the stress hormone – inside brain cells. High levels of cortisol are often seen in people with depression.
The trial medication is experimental.
®Xanamem is a registered trademark of Actinogen Medical Limited
Participation in the trial will be required for approximately 14 weeks (or about three months). This includes a screening period of up to 4 weeks, a treatment period of 6 weeks and a follow-up period of 4 weeks.
‘Randomized’ means that treatment will be assigned by chance (like flipping a coin) so that participants receive either the research project treatment or a placebo (no active ingredients).
Participants in the XanaCIDD trial will need to:
Clinials is a clinical trial recruitment service assisting with recruitment for the XanaCIDD MDD trial in Australia.
Click on the link below for further information on the XanaCIDD trial and an option to complete a questionnaire to determine eligibility for the trial, in which case the nearest trial site will contact the applicant directly.
Contact the nearest clinical trial site directly to discuss the trial and, if eligible, book in a screening visit with the site.
Main participation criteria:
Additonal information is available on clinicaltrials.gov (NCT05657691).
There is no cost to participate in this clinical trial.
Reimbursement for reasonable travel and incidental costs incurred attending clinic visits will be provided.